More info
Active ingredients
Plastoquinonyldecyltriphenylphosphonium bromide
Release form
Drops
Composition
Active ingredient: Plastoquinonyldecyltriphenylphosphonium bromide (PDTF) 0, 155 mcg. Auxiliary substances: Benzalkonium chloride 0, 1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrophosphate dihydrate 0, 81 mg, sodium, iodine, 9 mg, sodium hydrophosphate, 81 mg, sodium hydrogen, 9 mg, sodium hydride, calcium sulfate, 9 mg, sodium dihydrophosphate dihydrate 0, 81 mg; mcg
Pharmacological effect
Plastoquinonyldecyltriphenylphosphomy bromide (PDTP) is a derivative of plastoquinone, which is linked through a linker chain (CU) to the triphenylphosphine residue. PDTP in low (nanomolar) concentrations exhibits high antioxidant activity. It also has a stimulating effect on the process of tear production, epithelization, contributes to the stability of the tear film.
Pharmacokinetics
No human pharmacokinetic studies have been performed. In preclinical studies in animals, the distribution of PDTP in organs and tissues occurred within 48 hours after IV and intragastric administration. It was found that PDTP is present in the highest concentrations in the tissues of the kidney, liver and heart within 1 hour after administration. PDTP relatively quickly undergoes enzymatic cleavage and covalent binding to proteins.
Indications
The syndrome of "dry eye". The initial stage of age-related cataract.
Contraindications
Hypersensitivity to the components of the drug, age up to 18 years.
Use during pregnancy and lactation
Adequate controlled studies in pregnant and lactating women have not been conducted. It is not recommended to prescribe the drug during pregnancy. If you need an appointment during lactation for the period of treatment, breastfeeding should be stopped.
Dosage and administration
Dry eye syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of the course of treatment is determined by the doctor depending on the severity of the disease. The initial stage of age-related cataract: 1-2 drops of the drug in the conjunctival sac 3 times a day. Duration of treatment is 6 months. During drug therapy, an ophthalmologist should be monitored to assess the degree of disease progression and the need to continue conservative therapy.
Side effects
Allergic reactions. From the senses: perhaps a short-term burning sensation and cramps in the eyes after instillation.
Overdose
Data on overdose with local use are not available.
Interaction with other drugs
If necessary, you can apply simultaneously with other eye drops. In this case, the interval between instillations must be at least 5 minutes.
special instructions
Influence on the ability to drive vehicles and control mechanisms